AstraZeneca Plc $AZN Stock: Generali Asset Management SPA SGR Grows Holdings

Generali Asset Management SPA SGR grew its holdings in AstraZeneca Plc (NYSE:AZN) by 5.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 848,365 shares of the company’s stock after purchasing an additional 43,432 shares during the quarter. AstraZeneca comprises approximately 2.4% of Generali Asset Management SPA SGR’s portfolio, making the stock its 7th largest holding. Generali Asset Management SPA SGR’s holdings in AstraZeneca were worth $136,985,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Mascoma Wealth Management LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $26,000. Roxbury Financial LLC purchased a new position in AstraZeneca during the second quarter worth approximately $29,000. GK Wealth Management LLC purchased a new position in AstraZeneca during the third quarter worth approximately $31,000. Lynch Investment Planning LLC purchased a new position in AstraZeneca during the third quarter worth approximately $32,000. Finally, Resources Management Corp CT ADV acquired a new position in AstraZeneca during the first quarter worth $35,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

NYSE:AZN opened at $170.04 on Wednesday. The firm has a market capitalization of $263.71 billion, a PE ratio of 25.42 and a beta of 0.27. The business’s fifty day moving average price is $163.68 and its 200 day moving average price is $180.39. AstraZeneca Plc has a 12 month low of $153.41 and a 12 month high of $212.71.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. The firm’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.17 earnings per share. As a group, equities analysts anticipate that AstraZeneca Plc will post 10.23 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Zacks Research upgraded AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. HSBC lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Bank of America reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, July 1st. JPMorgan Chase & Co. reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of $206.67.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.